Logo image of REVB

REVELATION BIOSCIENCES INC (REVB) Stock Fundamental Analysis

NASDAQ:REVB - Nasdaq - US76135L6065 - Common Stock - Currency: USD

2.79  -0.04 (-1.24%)

After market: 2.7998 +0.01 (+0.35%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to REVB. REVB was compared to 560 industry peers in the Biotechnology industry. While REVB seems to be doing ok healthwise, there are quite some concerns on its profitability. REVB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year REVB has reported negative net income.
In the past year REVB has reported a negative cash flow from operations.
In the past 5 years REVB always reported negative net income.
In the past 5 years REVB always reported negative operating cash flow.
REVB Yearly Net Income VS EBIT VS OCF VS FCFREVB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

REVB's Return On Assets of -362.90% is on the low side compared to the rest of the industry. REVB is outperformed by 94.13% of its industry peers.
REVB's Return On Equity of -500.15% is on the low side compared to the rest of the industry. REVB is outperformed by 77.40% of its industry peers.
Industry RankSector Rank
ROA -362.9%
ROE -500.15%
ROIC N/A
ROA(3y)-141.62%
ROA(5y)-213.33%
ROE(3y)-450.21%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
REVB Yearly ROA, ROE, ROICREVB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 2K 4K 6K 8K 10K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for REVB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
REVB Yearly Profit, Operating, Gross MarginsREVB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

REVB has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, REVB has less shares outstanding
REVB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
REVB Yearly Shares OutstandingREVB Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M
REVB Yearly Total Debt VS Total AssetsREVB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

REVB has an Altman-Z score of -19.89. This is a bad value and indicates that REVB is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -19.89, REVB is not doing good in the industry: 83.81% of the companies in the same industry are doing better.
REVB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -19.89
ROIC/WACCN/A
WACCN/A
REVB Yearly LT Debt VS Equity VS FCFREVB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M -10M -15M

2.3 Liquidity

A Current Ratio of 3.61 indicates that REVB has no problem at all paying its short term obligations.
REVB has a Current ratio (3.61) which is in line with its industry peers.
REVB has a Quick Ratio of 3.61. This indicates that REVB is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of REVB (3.61) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.61
Quick Ratio 3.61
REVB Yearly Current Assets VS Current LiabilitesREVB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

REVB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 76.37%, which is quite impressive.
EPS 1Y (TTM)76.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, REVB will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.02% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y90.34%
EPS Next 2Y40.01%
EPS Next 3Y25.19%
EPS Next 5Y15.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
REVB Yearly Revenue VS EstimatesREVB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 50M 100M 150M
REVB Yearly EPS VS EstimatesREVB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -10K -20K -30K -40K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for REVB. In the last year negative earnings were reported.
Also next year REVB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
REVB Price Earnings VS Forward Price EarningsREVB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
REVB Per share dataREVB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80 -100

4.3 Compensation for Growth

A more expensive valuation may be justified as REVB's earnings are expected to grow with 25.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.01%
EPS Next 3Y25.19%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for REVB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REVELATION BIOSCIENCES INC

NASDAQ:REVB (7/11/2025, 8:00:02 PM)

After market: 2.7998 +0.01 (+0.35%)

2.79

-0.04 (-1.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-07 2025-08-07/bmo
Inst Owners2.08%
Inst Owner Change0%
Ins Owners2.79%
Ins Owner Change1.56%
Market Cap1.90M
Analysts82.86
Price TargetN/A
Short Float %16.63%
Short Ratio0.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)40.09%
Min EPS beat(2)10.25%
Max EPS beat(2)69.93%
EPS beat(4)3
Avg EPS beat(4)-6.86%
Min EPS beat(4)-178.64%
Max EPS beat(4)71%
EPS beat(8)6
Avg EPS beat(8)8.74%
EPS beat(12)10
Avg EPS beat(12)53.52%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-123.87%
EPS NQ rev (3m)25.31%
EPS NY rev (1m)-125.32%
EPS NY rev (3m)34.6%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.66
P/tB 0.66
EV/EBITDA N/A
EPS(TTM)-116.79
EYN/A
EPS(NY)-5.94
Fwd EYN/A
FCF(TTM)-26.88
FCFYN/A
OCF(TTM)-26.88
OCFYN/A
SpS0
BVpS4.24
TBVpS4.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -362.9%
ROE -500.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-141.62%
ROA(5y)-213.33%
ROE(3y)-450.21%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.61
Quick Ratio 3.61
Altman-Z -19.89
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.92%
EPS Next Y90.34%
EPS Next 2Y40.01%
EPS Next 3Y25.19%
EPS Next 5Y15.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y8.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-129.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-129.49%
OCF growth 3YN/A
OCF growth 5YN/A